Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | PON1 | P27169 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5903257 | 0.91 | ALDH1A1 (0.33) | PON1KDM4EMAPK1RAB9AKMT2A | |
| SCHEMBL1336683 | 0.82 | PGK1 (0.42) | PGK1PGK2PON1KDM4EMAPK1 | |
| SCHEMBL6063365 | 0.79 | ALDH1A1 (0.39) | PGK1PGK2PON1KDM4EMAPK1 | |
| SCHEMBL442987 | 0.79 | ALDH1A1 (0.42) | PGK1PGK2PON1KDM4EMAPK1 | |
| SCHEMBL2813643 | 0.76 | CYP3A4 (0.37) | MAPK1 | |
| SCHEMBL11431032 | 0.73 | CD44 (0.42) | PGK1PGK2PON1KDM4EMAPK1 | |
| SCHEMBL5872304 | 0.73 | PON1 (0.32) | PON1KDM4EMAPK1RAB9AKMT2A | |
| SCHEMBL1871392 | 0.70 | CYP3A4 (0.40) | MAPK1 | |
| SCHEMBL10718639 | 0.69 | CYP3A4 (0.33) | MAPK1 | |
| SCHEMBL14044125 | 0.68 | ALOX15 (0.39) | KDM4EMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7060851-B2 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2006-06-13 | — | — | US | disclosed |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. (US) | 2005-06-16 | — | — | US | disclosed |
| US-6849760-B2 | Method of preparing retroviral protease inhibitor intermediates | G. D. SEARLE & CO. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | G.D. SEARLE & CO. | 2003-09-11 | — | — | US | disclosed |
| US-6515162-B2 | Precipitating or crystallizing a salt from solution; suitable as intermediates for large scale production of enzyme inhibitors, e.g. hydroxyethylamine, hydroxyethylurea and hydroxyethylsulfonamide | G.D. SEARLE & CO. | 2003-02-04 | — | — | US | disclosed |
| US-20010047111-A1 | Method of preparing retroviral protease inhibitor intermediates | NG JOHN S (US) | 2001-11-29 | — | — | US | disclosed |
| EP-0804410-B1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | SEARLE & CO (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6201150-B1 | DIASTEREOMER PURIFICATION METHOD COMPRISING PREPARING AN ORGANIC ACID OR INORGANIC ACID SALT OF AN AMINO COMPOUND AND PRECIPITATING OR CRYSTALLIZING SAID SALT FROM A SOLUTION | G.D. SEARLE & CO. | 2001-03-13 | — | — | US | disclosed |
| US-5831117-A | ACID SALTS | G. D. SEARLE & CO. (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0804410-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996022275-A1 | METHOD OF PREPARING RETROVIRAL PROTEASE INHIBITOR INTERMEDIATES | G.D. SEARLE & CO. (US) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270855-A1 | Methods of preparing retroviral proteases inhibitor intermediates | ACE, REN, MME | PGK1 1306/4885PGK2 1933/4885PON1 176/4885 |
| US-20030171612-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | PGK1 1138/4885PGK2 1725/4885PON1 162/4885 |
| US-20010047111-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | PGK1 1138/4885PGK2 1725/4885PON1 162/4885 |
| US-20050131075-A1 | Method of preparing retroviral protease inhibitor intermediates | ACE, REN, MME | PGK1 1046/4885PGK2 1676/4885PON1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.